EIF2AK4 (GCN2)

Giulia Emanuelli1, JiaYi Zhu1, Wei Li2,3

  • 1Cambridge Institute for Medical Research (CIMR), University of Cambridge, Keith Peters Building, Biomedical Campus, Hills Rd, Cambridge CB2 0XY, United Kingdom.

PubMed
概括

研究人员评估了肺动脉高血压 (PAH) 中的EIF2AK4基因变异. 实验测试揭示了计算预测的局限性,确定了一些变异为非致病性,并将功能失调的GCN2变异分类为潜在的治疗策略.